参麦注射液治疗急性脑梗死有效性和安全性的Meta分析

Efficacy and Safety of Shenmai Injection in Treatment of Acute Cerebral Infarction: A Meta Analysis

目的:系统评价参麦注射液治疗急性脑梗死的有效性与安全性。方法:运用系统评价方法,检索参麦注射液治疗急性脑梗死的随机对照试验(RCT),筛选合格研究,评价研究质量,应用Jadad评分法进行质量评价,运用Meta分析、异质性检验、漏斗图、敏感性分析等方法分析相关数据。结果:经筛选纳入11项研究,共911例。Meta分析结果显示试验组临床总有效率[RR=1.24,95%CI(1.16,1.32)];恶化率[RR=0.22,95%CI(0.07,0.63)];CSS评分[MD=1.19,95%CI(1.07,1.84)];NHISS评分[MD=-3.44,95%CI(-4.87,-2.00)]ESS评分[MD=21.34,95%CI(20.05,22.63)];ADL评分[MD=9.47,95%CI(4.42,14.53)]。结论:参麦注射液有益于提高急性脑梗死的临床疗效。但由于本系统评价纳入研究质量低、样本量小且安全性不明确,尚需高质量随机对照试验进一步评价。

Objective：To evaluate the efficacy and safety of Shenmai Injection in the treatment of acute cerebral infarction. Methods：Use system evaluation method, retrieval of Shenmai Injection in the treatment of acute cerebral infarction randomized controlled trial （ RCT）, screening of qualified, quality evaluation, the Jadad score of quality evaluation, Meta analysis, heterogenei- ty test,funnel plots and sensitivity analysis method were used to analysis data. Results：A total of 911 cases were selected and in- cluded in the study. A total of 11 cases were included in the study. Treatment group＇s clinical total effective rate[ RR = 1.24,95% CI （1.16,1.32） ] ;rate of deterioration[ RR =0.22,95% CI （0.07,0.63）];CSS[MD = 1.19. （95% C1 1.07,1.84） ] ;NIHSS score [ MD = - 3.44 [ - 4.87, - 2.00 ] ]ESS score [MD = 21.34 20.05,22.63 ; ADL score [ MD = 9.47 4.42,14.53] Meta analy- sis was carried out. Conclusion：Shenmai Injection can improve the clinical curative effect of acute cerebral infarction. However, due to the low quality of the system evaluation, small sample size and safety is not clear which still need to further evaluate high quality randomized controlled trials.